Linnaeus Therapeutics Inc
Publicly observedHaddonfield, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Haddonfield | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Linnaeus Therapeutics Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | S4PUHLJ9SQ45 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant13 Jan 2025Publicly observed
NIH SBIR/STTR award: Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy
USD 999,960.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant13 Jan 2025Publicly observed
NIH SBIR/STTR award: Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy
USD 999,960.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.